Yale trial tests whether an arthritis drug can prevent Parkinson's in people with sleep disorders

Can we stop Parkinson’s years before the first tremor ever appears? A ground breaking clinical trial led by Yale School of Medicine is trying to do just that, using a familiar medication to tackle the condition at its very roots. For most people, the story of Parkinson’s begins with stiffness, slow movement, or shaking. Yet deep inside the body, the biological changes often start ten to twenty years earlier. One of the clearest early warnings is a sleep condition called REM sleep behaviour disorder, or RBD. During normal sleep, our brains switch off our muscles so our bodies stay still while we dream. In people with RBD, that natural off switch stops working. They physically act out their dreams, often kicking, punching, or shouting. Up to 90 percent of people who develop this sleep condition out of the blue eventually go on to develop Parkinson’s or a related brain condition. Scientists now know that sticky clumps of a protein called alpha synuclein start building up long before movement becomes difficult. These clumps often begin in the gut or the nose, slowly travelling up nerve pathways into the brainstem. The sleep control centres happen to sit right in their path, which is why sleep disturbances appear so early. Only years later do these protein clumps reach the areas of the brain that make dopamine, the chemical messenger needed for smooth movement. Current medicines do a wonderful job replacing lost dopamine, but they cannot stop the underlying spread of the protein. However, that long gap between early sleep troubles and movement issues offers an incredible opportunity: a chance to step in and protect brain cells before any lasting harm is done. Yale researchers noticed something fascinating when examining fluid from the spine in people with RBD. Their immune systems were on high alert, showing clear signs of inflammation that disappeared once full motor symptoms arrived. It looked remarkably like the early stages of multiple sclerosis, where rogue immune cells attack healthy tissue. In particular, the team found high activity around a chemical messenger called tumour necrosis factor, or TNF, which drives inflammation in conditions like rheumatoid arthritis and Crohn’s disease. Interestingly, people taking TNF blocking drugs for arthritis have a much lower chance of developing Parkinson’s. The scientists realised that the immune system might actually be causing collateral damage in the brain, attacking healthy nerve cells while trying to clear away the sticky proteins. To test this idea, researchers created the PRISMS study. The trial is testing adalimumab, a widely used anti inflammatory injection best known as Humira. Across fifteen centres in the United States and Canada, the study is welcoming volunteers aged 50 to 80 who have confirmed RBD and a reduced sense of smell, a combination that strongly shows the protein changes are underway. Over two years, participants receive either the medication or a dummy injection every fortnight. Alongside regular health check ups, researchers will use advanced brain scans to watch how brain cells produce dopamine and burn energy. If the medication can calm the immune system, protect energy levels in the brain, and keep dopamine cells healthy, it could prove that stopping inflammation early alters the course of the condition entirely. By stepping in during this quiet, early window, the team hopes to turn the management of Parkinson’s on its head, moving away from simply managing symptoms and taking a vital step towards genuine prevention.